[Clinical contribution of new basal analogue insulin].
Chronic long term hyperglycemia plays a key role in the pathogenesis of micro and macrovascular complications. The UKPDS study and its further analysis has proved that reduction of the value of glycated hemoglobin by 1 % leads to a 14 % reduction of the risk of myocardial infarction and a 37 % reduction of the risk of microvascular complications. Effective control of glycaemia, optimal value of pre-prandial, postprandial glycaemia, and low variability from the start of the disease has a long term beneficial impact. The therapy of basal insulin analogues ranks among the recommended procedures for achieving control. The new insulin analogues (insulin glargin 300 U/ml, insulin degludec) have a longer effect, practically a peakless course, lower variability, lower risk of hypoglycemia events and better application technique with greater flexibility of administration. The pharmacokinetic and pharmacodynamics properties provide new quality in the chronic therapy of people with type 1 and 2 diabetes.


BACKGROUND
diabetes mellitus - glycemia control - hypoglycemia - new basal insulin analogues.
Alena
A
Adamíková
D001786:Blood Glucose / Q000378:metabolism; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D006943:Hyperglycemia / Q000517:prevention & control; D007003:Hypoglycemia / Q000517:prevention & control; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000069036:Insulin Glargine / Q000627:therapeutic use*; D049528:Insulin, Long-Acting / Q000627:therapeutic use*; D019518:Postprandial Period
D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting; C571886:insulin degludec